HYBRID EVENT: Join us in person in Tokyo, Japan or attend virtually from anywhere.
The interaction between aging and cancer therapies involves complex changes in how older adults metabolize and respond to treatments. As individuals age, their liver and kidney functions may decline, which can affect drug clearance and increase the risk of toxicity from chemotherapy and other therapies. Additionally, age-related changes in the immune system can alter the body’s response to immunotherapy, which may not be as effective in older adults. Understanding these interactions is essential for developing therapies that are specifically designed for the aging population. This includes adjusting dosages, selecting more targeted therapies, and closely monitoring side effects to ensure the treatment is both effective and safe for elderly patients.
